These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

477 related articles for article (PubMed ID: 35144680)

  • 21. Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion.
    Kawaguchi T; Sonoda Y; Shibahara I; Saito R; Kanamori M; Kumabe T; Tominaga T
    J Neurooncol; 2016 Sep; 129(3):505-514. PubMed ID: 27401154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. IDH clonal heterogeneity segregates a subgroup of non-1p/19q codeleted gliomas with unfavourable clinical outcome.
    Luo S; Zhu S; Liao J; Zhang Y; Hou X; Luo T; Zhao E; Xu J; Pang L; Liang X; Xiao Y; Li X
    Neuropathol Appl Neurobiol; 2021 Apr; 47(3):394-405. PubMed ID: 33098109
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The presence of TIM-3 positive cells in WHO grade III and IV astrocytic gliomas correlates with isocitrate dehydrogenase mutation status.
    Sørensen MD; Nielsen O; Reifenberger G; Kristensen BW
    Brain Pathol; 2021 May; 31(3):e12921. PubMed ID: 33244787
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The clinical value of proneural, classical and mesenchymal protein signatures in WHO 2021 adult-type diffuse lower-grade gliomas.
    Dénes A; Bontell TO; Barchéus H; Vega SF; Carén H; Lindskog C; Jakola AS; Smits A
    PLoS One; 2023; 18(5):e0285732. PubMed ID: 37192181
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas.
    Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST
    Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Decoupling genetics, lineages, and microenvironment in IDH-mutant gliomas by single-cell RNA-seq.
    Venteicher AS; Tirosh I; Hebert C; Yizhak K; Neftel C; Filbin MG; Hovestadt V; Escalante LE; Shaw ML; Rodman C; Gillespie SM; Dionne D; Luo CC; Ravichandran H; Mylvaganam R; Mount C; Onozato ML; Nahed BV; Wakimoto H; Curry WT; Iafrate AJ; Rivera MN; Frosch MP; Golub TR; Brastianos PK; Getz G; Patel AP; Monje M; Cahill DP; Rozenblatt-Rosen O; Louis DN; Bernstein BE; Regev A; Suvà ML
    Science; 2017 Mar; 355(6332):. PubMed ID: 28360267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiological characteristics based on isocitrate dehydrogenase mutations and 1p/19q codeletion in grade II and III gliomas.
    Yamauchi T; Ohno M; Matsushita Y; Takahashi M; Miyakita Y; Kitagawa Y; Kondo E; Tsushita N; Satomi K; Yoshida A; Ichimura K; Narita Y
    Brain Tumor Pathol; 2018 Jul; 35(3):148-158. PubMed ID: 29922974
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas.
    Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF
    EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The T2-FLAIR-mismatch sign as an imaging biomarker for IDH and 1p/19q status in diffuse low-grade gliomas: a systematic review with a Bayesian approach to evaluation of diagnostic test performance.
    Goyal A; Yolcu YU; Goyal A; Kerezoudis P; Brown DA; Graffeo CS; Goncalves S; Burns TC; Parney IF
    Neurosurg Focus; 2019 Dec; 47(6):E13. PubMed ID: 31786548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Absolute quantification of tumor-infiltrating immune cells in high-grade glioma identifies prognostic and radiomics values.
    Kim AR; Choi KS; Kim MS; Kim KM; Kang H; Kim S; Chowdhury T; Yu HJ; Lee CE; Lee JH; Lee ST; Won JK; Kim JW; Kim YH; Kim TM; Park SH; Choi SH; Shin EC; Park CK
    Cancer Immunol Immunother; 2021 Jul; 70(7):1995-2008. PubMed ID: 33416947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular subtyping reveals immune alterations in IDH wild-type lower-grade diffuse glioma.
    Wu F; Li GZ; Liu HJ; Zhao Z; Chai RC; Liu YQ; Jiang HY; Zhai Y; Feng YM; Li RP; Zhang W
    J Pathol; 2020 Jul; 251(3):272-283. PubMed ID: 32418210
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas.
    Leu K; Ott GA; Lai A; Nghiemphu PL; Pope WB; Yong WH; Liau LM; Cloughesy TF; Ellingson BM
    J Neurooncol; 2017 Aug; 134(1):177-188. PubMed ID: 28547590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Isocitrate Dehydrogenase, Patient-Reported Outcomes, and Cognitive Functioning of Glioma Patients: a Systematic Review.
    Bunevicius A; Miller J; Parsons M
    Curr Oncol Rep; 2020 Sep; 22(12):120. PubMed ID: 32965568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Neuro-radiological characteristics of adult diffuse grade II and III insular gliomas classified according to WHO 2016.
    Compes P; Tabouret E; Etcheverry A; Colin C; Appay R; Cordier N; Mosser J; Chinot O; Delingette H; Girard N; Dufour H; Metellus P; Figarella-Branger D
    J Neurooncol; 2019 May; 142(3):511-520. PubMed ID: 30756272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.
    Grewal EP; Richardson LGK; Sun J; Ramapriyan R; Martinez-Lage M; Miller JJ; Carter BS; Cahill DP; Curry WT; Choi BD
    Clin Cancer Res; 2024 Sep; 30(18):4068-4076. PubMed ID: 39042445
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Integrated molecular analysis reveals hypermethylation and overexpression of HOX genes to be poor prognosticators in isocitrate dehydrogenase mutant glioma.
    Mamatjan Y; Voisin MR; Nassiri F; Moraes FY; Bunda S; So J; Salih M; Shirahata M; Ono T; Shimizu H; Schrimpf D; von Deimling A; Aldape KD; Zadeh G
    Neuro Oncol; 2023 Nov; 25(11):2028-2041. PubMed ID: 37474126
    [TBL] [Abstract][Full Text] [Related]  

  • 37. IDH mutation status is associated with distinct vascular gene expression signatures in lower-grade gliomas.
    Zhang L; He L; Lugano R; Roodakker K; Bergqvist M; Smits A; Dimberg A
    Neuro Oncol; 2018 Oct; 20(11):1505-1516. PubMed ID: 29846705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Integrated diagnostics of diffuse astrocytic and oligodendroglial tumors.
    Malzkorn B; Reifenberger G
    Pathologe; 2019 Jun; 40(Suppl 1):9-17. PubMed ID: 31025086
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted next-generation sequencing of adult gliomas for retrospective prognostic evaluation and up-front diagnostics.
    Petersen JK; Boldt HB; Sørensen MD; Blach S; Dahlrot RH; Hansen S; Burton M; Thomassen M; Kruse T; Poulsen FR; Andreasen L; Hager H; Ulhøi BP; Lukacova S; Reifenberger G; Kristensen BW
    Neuropathol Appl Neurobiol; 2021 Feb; 47(1):108-126. PubMed ID: 32696543
    [TBL] [Abstract][Full Text] [Related]  

  • 40. B2M overexpression correlates with malignancy and immune signatures in human gliomas.
    Zhang H; Cui B; Zhou Y; Wang X; Wu W; Wang Z; Dai Z; Cheng Q; Yang K
    Sci Rep; 2021 Mar; 11(1):5045. PubMed ID: 33658560
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.